{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T14:40:49Z","timestamp":1784644849842,"version":"3.55.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.clml.2016.12.004","type":"journal-article","created":{"date-parts":[[2017,1,10]],"date-time":"2017-01-10T14:32:14Z","timestamp":1484058734000},"page":"225-230","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Posterior Reversible Encephalopathy Syndrome Associated With Dose-adjusted EPOCH (Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) Chemotherapy"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7654-5128","authenticated-orcid":false,"given":"Abby E.","family":"Floeter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amila","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc C.","family":"Chamberlain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C.","family":"Hendrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay K.","family":"Gopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan D.","family":"Cassaday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2016.12.004_bib1","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1182\/blood.V99.8.2685","article-title":"Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy","volume":"99","author":"Wilson","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.12.004_bib2","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1182\/blood-2009-08-231613","article-title":"Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma","volume":"115","author":"Sparano","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.12.004_bib3","doi-asserted-by":"crossref","first-page":"758","DOI":"10.3324\/haematol.2011.056531","article-title":"A\u00a0Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype","volume":"97","author":"Wilson","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2016.12.004_bib4","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1200\/JCO.2007.13.1391","article-title":"Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers","volume":"26","author":"Wilson","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.12.004_bib5","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1214561","article-title":"Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma","volume":"368","author":"Dunleavy","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2016.12.004_bib6","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1055\/s-0031-1277990","article-title":"Posterior reversible encephalopathy syndrome: a review","volume":"31","author":"Feske","year":"2011","journal-title":"Semin Neurol"},{"key":"10.1016\/j.clml.2016.12.004_bib7","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1212\/WNL.51.5.1369","article-title":"Posterior leukoencephalopathy without severe hypertension: utility of diffusion-weighted MRI","volume":"51","author":"Ay","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.clml.2016.12.004_bib8","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0887-8994(98)00148-9","article-title":"Posterior leukoencephalopathy syndrome may not be reversible","volume":"20","author":"Antunes","year":"1999","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.clml.2016.12.004_bib9","first-page":"1038","article-title":"Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images","volume":"23","author":"Covarrubias","year":"2002","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.clml.2016.12.004_bib10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1445-5994.2004.00750.x","article-title":"Reversible posterior leukoencephalopathy syndrome: a misnomer reviewed","volume":"35","author":"Stott","year":"2005","journal-title":"Int Med J"},{"key":"10.1016\/j.clml.2016.12.004_bib11","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ncl.2011.05.005","article-title":"Toxic leukoencephalopathies","volume":"29","author":"Tormoehlen","year":"2011","journal-title":"Neurol Clin"},{"key":"10.1016\/j.clml.2016.12.004_bib12","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s11912-014-0383-3","article-title":"Posterior reversible encephalopathy syndrome: a neurologic phenomenon in cancer patients","volume":"16","author":"Le","year":"2014","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.clml.2016.12.004_bib13","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJM199602223340803","article-title":"A\u00a0reversible posterior leukoencephalopathy syndrome","volume":"334","author":"Hinchey","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2016.12.004_bib14","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.msard.2014.08.004","article-title":"Posterior reversible encephalopathy syndrome masquerading as progressive multifocal leukoencephalopathy in rituximab treated neuromyelitis optica","volume":"3","author":"Berger","year":"2014","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.clml.2016.12.004_bib15","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11912-008-0013-z","article-title":"Reversible posterior leukoencephalopathy syndrome in cancer","volume":"10","author":"Vaughn","year":"2008","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.clml.2016.12.004_bib16","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/ajh.23402","article-title":"Tacrolimus-associated posterior reversible encephalopathy syndrome in hematopoietic allogeneic stem cell transplantation","volume":"88","author":"Hammerstrom","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2016.12.004_bib17","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1023\/A:1012248800195","article-title":"Reversible posterior leukoencephalopathy syndrome following CHOP chemotherapy for diffuse large B-cell lymphoma","volume":"12","author":"Edwards","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2016.12.004_bib18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1365-2141.2010.08189.x","article-title":"Images in haematology: irreversible blindness secondary to posterior reversible encephalopathy syndrome following CHOP combination chemotherapy","volume":"150","author":"Hemmaway","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2016.12.004_bib19","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00277-009-0783-x","article-title":"Reversible posterior leukoencephalopathy syndrome following R-CHOP therapy for diffuse large B-cell lymphoma","volume":"89","author":"Hosoi","year":"2010","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2016.12.004_bib20","doi-asserted-by":"crossref","first-page":"292","DOI":"10.4103\/0973-1482.98993","article-title":"Methotrexate-induced acute toxic leukoencephalopathy","volume":"8","author":"Salkade","year":"2012","journal-title":"J\u00a0Cancer Res Ther"},{"key":"10.1016\/j.clml.2016.12.004_bib21","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/rheumatology\/keh305","article-title":"A\u00a0case of reversible posterior leucoencephalopathy syndrome after rituximab infusion","volume":"43","author":"Mavragani","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clml.2016.12.004_bib22","doi-asserted-by":"crossref","first-page":"427","DOI":"10.4065\/mcp.2009.0590","article-title":"Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings","volume":"85","author":"Fugate","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2016.12.004_bib23","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1212\/WNL.0b013e3181dc1af3","article-title":"Posterior reversible encephalopathy syndrome after rituximab infusion in neuromyelitis optica","volume":"74","author":"Sanchez-Carteyron","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.clml.2016.12.004_bib24","doi-asserted-by":"crossref","first-page":"513","DOI":"10.4066\/AMJ.2011.627","article-title":"Rituximab as a possible cause of posterior reversible encephalopathy syndrome","volume":"4","author":"Siddiqi","year":"2011","journal-title":"Australas Med J"},{"key":"10.1016\/j.clml.2016.12.004_bib25","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11060-016-2078-0","article-title":"Posterior reversible encephalopathy syndrome in cancer patients: a single institution retrospective study","volume":"128","author":"Kamiya-Matsuoka","year":"2016","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.clml.2016.12.004_bib26","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/ajh.20147","article-title":"Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignancies","volume":"77","author":"Tam","year":"2004","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2016.12.004_bib27","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1634\/theoncologist.2014-0149","article-title":"Posterior reversible encephalopathy syndrome in patients with cancer","volume":"20","author":"Singer","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2016.12.004_bib28","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1177\/0883073809332705","article-title":"Posterior reversible encephalopathy syndrome associated with methotrexate neurotoxicity: conventional magnetic resonance and diffusion-weighted imaging findings","volume":"24","author":"Dicuonzo","year":"2009","journal-title":"J\u00a0Child Neurol"},{"key":"10.1016\/j.clml.2016.12.004_bib29","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ejpn.2010.01.003","article-title":"Posterior reversible encephalopathy syndrome in paediatric leukaemia","volume":"14","author":"Panis","year":"2010","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.clml.2016.12.004_bib30","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1365-2710.2010.01207.x","article-title":"Methotrexate-induced posterior reversible encephalopathy syndrome","volume":"36","author":"Aradillas","year":"2011","journal-title":"J\u00a0Clin Pharm Ther"},{"key":"10.1016\/j.clml.2016.12.004_bib31","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1200\/JCO.2013.53.0808","article-title":"Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia","volume":"32","author":"Bhojwani","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.12.004_bib32","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/annonc\/mdm466","article-title":"Clinical and radiological characteristics of methotrexate-induced acute encephalopathy in pediatric patients with cancer","volume":"19","author":"Inaba","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2016.12.004_bib33","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.pediatrneurol.2010.05.005","article-title":"Reversible posterior leukoencephalopathy induced by cancer chemotherapy","volume":"43","author":"Baytan","year":"2010","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.clml.2016.12.004_bib34","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/2042098612453849","article-title":"Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps","volume":"3","author":"Zaheer","year":"2012","journal-title":"Ther Adv Drug Saf"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016306449?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016306449?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:28:18Z","timestamp":1761870498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265016306449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S2152265016306449"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2016.12.004","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Posterior Reversible Encephalopathy Syndrome Associated With Dose-adjusted EPOCH (Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) Chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2016.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}